MDMA THERAPY

In the public discussion about psychedelic therapy for cancer, the focus is often on the patient: can a substance like LSD, psilocybin, or MDMA help with existential anxiety, depression, or coping with the end of life? However, surrounding every patient there are usually one or more loved ones as well. Informal caregivers handle practical matters, offer emotional support, and absorb a great deal of tension. Precisely for this reason, it is relevant to include their perspective in research and in the way therapy is designed.

A recent scientific article focuses on precisely that: the experiences of caregivers of cancer patients participating in an LSD microdosing trial. Therefore, the primary focus is not on the pharmacological effects of LSD, but rather on the social context of an experimental treatment and its impact on relationships, communication, and burden. In this article, we outline the key insights, place them in context, and translate them into practical considerations regarding safety and harm reduction within psychedelic programs.

What exactly did this article investigate?

The study is qualitative in design and examines caregivers of people with (advanced) cancer who participated in an LSD microdosing study. This means that participants received repeated very low doses of LSD within a research setting, with guidance and monitoring according to the study protocol.

It is important to emphasize: this is not an efficacy study that draws firm conclusions about the effectiveness of LSD microdosing in cancer. Rather, the core question is: how do loved ones experience the process, what changes in the relationship, and what challenges do they encounter? This is valuable information, because psychedelic therapy does not only take place in a person’s “inner world,” but also within a network of relationships, expectations, and daily care.

Anyone who wishes to read the original piece can do so via this summary of the article.

The relationship as the “working context” of therapy

A striking theme in the results is that informal caregivers perceive the relationship with the patient as central. Several caregivers described more connection, openness, and meaningful conversations. This can manifest as more honest communication about fears, wishes, and saying goodbye, but also as more “ordinary” closeness, such as being able to be silent together without the need for an immediate solution.

This is an important nuance in the debate surrounding psychedelics: even if a substance in itself has no proven effect in a specific context, the surrounding process can certainly influence how people cope with illness. The setting (support, safety, expectations) and the social environment (loved ones, care team) color the experience. In research into psychedelic therapy, this is often summarized as set & setting, but this study shows that there is also a relational layer underneath: the dynamic between patient and caregiver.

Hope, finding meaning and “living in the moment”

In this study, informal caregivers regularly reported that the process could offer hope. This is not proof that the treatment influences disease outcomes, but it does say something about the psychological and existential impact people can experience in a palliative context. Hope can mean: more space to enjoy small moments, the feeling that something is still possible, or that there is support that looks beyond just physical symptoms.

In addition, the act of finding meaning came to the fore. With serious illness, the perspective on time, identity, and the future often changes. If a therapeutic process (with or without psychedelics) helps people put into words what matters, this can also provide relief for caregivers. Not because the situation becomes “good,” but because the relationship and communication can become more bearable.

The dark side: insecurity, stigma, and emotional burden

The article also describes challenging aspects. Informal caregivers had to cope with uncertainty: about the disease, about the outcome of the study, and about exactly what microdosing does. Uncertainty is already high in cancer care, and an experimental process can amplify that tension. For some caregivers, this entails extra responsibility, for example by contributing ideas, monitoring for signs, or coping with emotional peaks.

Stigma is a second important point. For many people, psychedelics still evoke associations with recreational use, risks, or “illegal goings-on.” As a result, caregivers may be reluctant to talk to others about it, or conversely, experience tension within the family: one sees it as an opportunity, the other as unwise. This, too, is part of the reality of therapy in this field, especially as long as many applications take place primarily within research.

Finally, there is the emotional burden. Informal caregiving is often intensive and can lead to burnout, poor sleep, and the feeling of always being “on.” A therapeutic process can offer support, but it can also add extra logistics and tension. It is important to acknowledge this duality honestly, as it helps maintain realistic expectations.

What does this mean for the practice of psychedelic therapy?

Although the research focuses on LSD microdosing, the lessons are more broadly applicable to psychedelic therapy as a field, including pathways with other substances. Some practical implications:

1) Involve loved ones where appropriate and desired. Not every patient wants to or is able to involve loved ones, and privacy and autonomy remain paramount. However, where appropriate, providing psycho-education to caregivers can be helpful: what is the goal of the process, what is experimental, and what reactions might occur?

2) Make room for expectation management. Informal caregivers may hope for “a breakthrough,” less anxiety, or better communication. At the same time, the illness remains a reality. Clear language about what is and is not known can reduce disappointment and pressure.

3) Pay attention to capacity and limits. Informal caregivers sometimes need support themselves. A process that focuses solely on the patient can unintentionally increase the burden. A simple check-in with the caregiver (with the patient's permission) can already help recognize signs of burnout.

4) Harm reduction is also relational. Harm reduction is not just about substances and dosages, but also about context: family stress, communication patterns, and stigma. Discussing these aspects can reduce risks, for example by making agreements about who the point of contact is, what to do in case of unrest, and how to handle difficult conversations.

Where does MDMA fit into this, and what is currently possible?

This article is about LSD microdosing, but many people are reading along out of interest in other forms of psychedelic therapy, including MDMA-assisted therapy. It is important to remain factual regarding the state of affairs: MDMA sessions can currently only be discussed and structured within scientific research or in clinical practice in a harm-reduction context. This means that there is no general, standard treatment route like with standard psychotherapy, and that applications outside of research do not have the same framework as hospital or mental healthcare treatment.

Anyone considering a guided session would generally do well to critically examine screening, guidance, aftercare, transparency regarding risks, and the boundaries of what is and is not proven. If you wish to explore how a session is typically structured in a harm-reduction context and what points of attention are involved, you can find information and potentially register via https://mdmatherapie.nl/aanmelden-mdma-sessie/.

Conclusion

This study of caregivers surrounding an LSD microdosing trial in cancer primarily shows that psychedelic therapy does not take place in a vacuum. The relationship between patient and caregiver can deepen, with greater openness, connection, and meaningful conversations, while at the same time uncertainty, stigma, and emotional burden remain real challenges. Perhaps the most important lesson is that “therapy” here is not just about a substance, but about guidance, context, and carefully involving the people closest to the patient.